S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
Silicon Motion Proves That AI in Motion Stays in Motion
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
Silicon Motion Proves That AI in Motion Stays in Motion
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
Silicon Motion Proves That AI in Motion Stays in Motion
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
Silicon Motion Proves That AI in Motion Stays in Motion

Crinetics Pharmaceuticals (CRNX) News Today

$43.49
-0.19 (-0.43%)
(As of 04/16/2024 ET)
SourceHeadline
MarketBeat logoCrinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 7.8%
americanbankingnews.com - April 14 at 6:08 AM
finanznachrichten.de logoCrinetics Pharmaceuticals, Inc.: Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
finanznachrichten.de - April 12 at 8:19 AM
finance.yahoo.com logoCrinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - April 11 at 8:29 PM
globenewswire.com logoCrinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com - April 11 at 4:05 PM
marketbeat.com logoCrinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Up 5.1%
marketbeat.com - April 11 at 4:01 PM
insidertrades.com logoCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) CEO Sells $2,013,560.67 in Stock
insidertrades.com - April 9 at 4:20 AM
marketbeat.com logoVanguard Group Inc. Increases Stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
marketbeat.com - April 5 at 4:07 AM
marketbeat.com logoCrinetics Pharmaceuticals (NASDAQ:CRNX) Sees Large Volume Increase
marketbeat.com - April 3 at 4:50 PM
insidertrades.com logoCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Director Stephanie Okey Sells 17,500 Shares
insidertrades.com - April 3 at 4:58 AM
marketbeat.com logoCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of "Moderate Buy" from Analysts
marketbeat.com - April 3 at 2:20 AM
marketbeat.com logoCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Sees Significant Growth in Short Interest
marketbeat.com - April 2 at 7:18 PM
marketbeat.com logoCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Director Sells $811,650.00 in Stock
marketbeat.com - April 2 at 6:38 PM
marketbeat.com logoCrinetics Pharmaceuticals (NASDAQ:CRNX) Hits New 1-Year High at $48.00
marketbeat.com - April 1 at 9:26 AM
investing.com logoCrinetics Pharmaceuticals COO sells shares worth over $1.4 million
investing.com - March 28 at 6:13 PM
insidermonkey.com logoInsiders Are Dumping These 5 Healthcare Stocks
insidermonkey.com - March 28 at 1:12 PM
marketbeat.com logoCrinetics Pharmaceuticals' (CRNX) "Market Outperform" Rating Reaffirmed at JMP Securities
marketbeat.com - March 28 at 11:29 AM
finance.yahoo.com logoInsider Sell: COO Jeff Knight Sells 32,359 Shares of Crinetics Pharmaceuticals Inc (CRNX)
finance.yahoo.com - March 27 at 10:54 AM
insidertrades.com logoInsider Selling: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) COO Sells 32,359 Shares of Stock
insidertrades.com - March 27 at 4:57 AM
marketbeat.com logoCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) COO Jeff E. Knight Sells 32,359 Shares
marketbeat.com - March 26 at 6:41 PM
insidertrades.com logoCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Dana Pizzuti Sells 15,089 Shares
insidertrades.com - March 23 at 8:48 AM
marketbeat.com logoCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Sells $664,821.34 in Stock
marketbeat.com - March 22 at 8:10 PM
finance.yahoo.com logoDirector Matthew Fust Sells 60,000 Shares of Crinetics Pharmaceuticals Inc (CRNX)
finance.yahoo.com - March 22 at 7:30 PM
finance.yahoo.com logoInsider Sell: Chief Medical and Development Officer Dana Pizzuti Sells 15,089 Shares of ...
finance.yahoo.com - March 22 at 7:30 PM
marketbeat.com logoEquities Analysts Set Expectations for Crinetics Pharmaceuticals, Inc.'s FY2025 Earnings (NASDAQ:CRNX)
marketbeat.com - March 22 at 8:38 AM
insidertrades.com logoCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) CFO Marc Wilson Sells 6,942 Shares
insidertrades.com - March 21 at 9:46 AM
markets.businessinsider.com logoBuy Rating Affirmed for Crinetics Pharmaceuticals on Paltusotine’s Clinical Success and Market Potential
markets.businessinsider.com - March 21 at 7:34 AM
markets.businessinsider.com logoBuy Rating Affirmed for Crinetics Pharmaceuticals Amid Impressive Paltusotine Trial Results
markets.businessinsider.com - March 21 at 7:34 AM
finance.yahoo.com logoCrinetics Pharmaceuticals Inc CFO Marc Wilson Sells 6,942 Shares
finance.yahoo.com - March 21 at 7:34 AM
marketbeat.com logoCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) CFO Sells $297,881.22 in Stock
marketbeat.com - March 20 at 7:36 PM
marketbeat.com logoCrinetics Pharmaceuticals (NASDAQ:CRNX) Shares Gap Down to $45.18
marketbeat.com - March 20 at 12:45 PM
marketbeat.com logoCrinetics Pharmaceuticals (NASDAQ:CRNX) Price Target Raised to $55.00
marketbeat.com - March 20 at 12:32 PM
marketbeat.com logoCrinetics Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:CRNX)
marketbeat.com - March 20 at 11:34 AM
marketbeat.com logoShort Interest in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Increases By 5.1%
marketbeat.com - March 19 at 9:20 PM
marketwatch.com logoCrinetics Pharmaceuticals Up on Positive Results for Acromegaly Drug Trial
marketwatch.com - March 19 at 8:38 PM
markets.businessinsider.com logoAnalysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX) and Biogen (BIIB)
markets.businessinsider.com - March 19 at 3:38 PM
benzinga.com logoEndocrine Disease-Focused Crinetics Pharmaceuticals Stock Soars On Tuesday - Here's Why
benzinga.com - March 19 at 3:38 PM
finance.yahoo.com logoCrinetics Stock Jets 16% Higher, Reversing A Three-Week Decline On Its Phase 3 Win
finance.yahoo.com - March 19 at 3:38 PM
marketbeat.com logoCrinetics Pharmaceuticals (NASDAQ:CRNX) Receives Buy Rating from HC Wainwright
marketbeat.com - March 19 at 12:41 PM
marketbeat.com logoCrinetics Pharmaceuticals (NASDAQ:CRNX) Shares Gap Up to $37.93
marketbeat.com - March 19 at 11:51 AM
markets.businessinsider.com logoCrinetics Pharma Reports Positive Results From Phase 3 Studies Of Paltusotine For Acromegaly
markets.businessinsider.com - March 19 at 8:17 AM
reuters.com logoCrinetics Pharma's hormonal disorder drug meets main goal in late-stage study
reuters.com - March 19 at 8:17 AM
msn.com logoCrinetics gains as late-stage trial for lead drug succeeds
msn.com - March 19 at 8:17 AM
finance.yahoo.com logoCrinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
finance.yahoo.com - March 19 at 8:17 AM
finance.yahoo.com logoUPDATE 2-Crinetics' hormonal disorder drug succeeds in late-stage study
finance.yahoo.com - March 19 at 8:17 AM
finance.yahoo.com logoBiotech Stock Crinetics Jets Higher On Second Phase 3 Trial Win
finance.yahoo.com - March 19 at 8:17 AM
globenewswire.com logoCrinetics' Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
globenewswire.com - March 19 at 6:00 AM
marketbeat.com logoCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Purchased by Wellington Management Group LLP
marketbeat.com - March 18 at 4:53 AM
markets.businessinsider.com logoBuy Rating Affirmed for Crinetics Pharmaceuticals as Paltusotine Shows Promising Phase 2 Results and Market Potential
markets.businessinsider.com - March 13 at 9:53 AM
seekingalpha.com logoCrinetics reports encouraging Phase 2 data for carcinoid syndrome drug
seekingalpha.com - March 12 at 7:01 PM
globenewswire.com logoCrinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
globenewswire.com - March 12 at 4:05 PM
Get Crinetics Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter.

AI “wealth window” is closing soon! (Ad)

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…

CRNX Media Mentions By Week

CRNX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CRNX
News Sentiment

0.51

0.66

Average
Medical
News Sentiment

CRNX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CRNX Articles
This Week

5

4

CRNX Articles
Average Week

Get Crinetics Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:CRNX) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners